PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23871542-8	2013	Increasing GAG sulfation improved equine tenocyte metabolic activity in normal serum (10% FBS), low serum (1% FBS), and IGF-1 supplemented media conditions.	Glycosaminoglycans	11-14	insulin like growth factor 1	Equus caballus	120-125	
23871542-9	2013	Notably, previously reported dose-dependent changes in tenocyte bioactivity to soluble IGF-1 within the CG scaffold were replicated by using a single dose of soluble IGF-1 in scaffolds containing increasingly sulfated GAGs.	Glycosaminoglycans	218-222	insulin like growth factor 1	Equus caballus	166-171	
14756373-6	2004	RESULTS: TA and IGF-1 in combination inhibited the IL-1-induced release of PG matrix components (glycosaminoglycan or GAG) from the articular cartilage, as well as producing a significant increase in GAG synthesis.	Glycosaminoglycans	97-114	insulin like growth factor 1	Equus caballus	16-21	
14756373-6	2004	RESULTS: TA and IGF-1 in combination inhibited the IL-1-induced release of PG matrix components (glycosaminoglycan or GAG) from the articular cartilage, as well as producing a significant increase in GAG synthesis.	Glycosaminoglycans	118-121	insulin like growth factor 1	Equus caballus	16-21	
14756373-6	2004	RESULTS: TA and IGF-1 in combination inhibited the IL-1-induced release of PG matrix components (glycosaminoglycan or GAG) from the articular cartilage, as well as producing a significant increase in GAG synthesis.	Glycosaminoglycans	200-203	insulin like growth factor 1	Equus caballus	16-21	
11843134-8	2002	Highest concentration of IGF-1 (25 microg/ml) significantly increased total DNA content, glycosaminoglycan (GAG) content, GAG synthesis, and size of proteoglycan monomers produced, compared with cultures supplemented with 12.5 microg of IGF-1/ml or untreated cultures.	Glycosaminoglycans	89-106	insulin like growth factor 1	Equus caballus	25-30	
11843134-8	2002	Highest concentration of IGF-1 (25 microg/ml) significantly increased total DNA content, glycosaminoglycan (GAG) content, GAG synthesis, and size of proteoglycan monomers produced, compared with cultures supplemented with 12.5 microg of IGF-1/ml or untreated cultures.	Glycosaminoglycans	108-111	insulin like growth factor 1	Equus caballus	25-30	
11843134-8	2002	Highest concentration of IGF-1 (25 microg/ml) significantly increased total DNA content, glycosaminoglycan (GAG) content, GAG synthesis, and size of proteoglycan monomers produced, compared with cultures supplemented with 12.5 microg of IGF-1/ml or untreated cultures.	Glycosaminoglycans	122-125	insulin like growth factor 1	Equus caballus	25-30	
10772110-7	2000	In general, IGF-1 decreased total and labeled GAG released into the medium, compared with IL-1alpha-treated explants (positive-control sample).	Glycosaminoglycans	46-49	insulin like growth factor 1	Equus caballus	12-17	
10772110-9	2000	A significant increase in total and newly synthesized GAG in the explants at termination of the experiment was observed with 500 ng of IGF-1/ml.	Glycosaminoglycans	54-57	insulin like growth factor 1	Equus caballus	135-140	
10772110-10	2000	Labeled GAG remaining in explants was greater with treatment at 50 ng of IGF-1/ml, compared with treatment with IL-1alpha alone.	Glycosaminoglycans	8-11	insulin like growth factor 1	Equus caballus	73-78	
9140562-3	1997	PROCEDURE: Triamcinolone acetonide and IGF-1 effects were evaluated by assessing: matrix responses by sulfated glycosaminoglycan (GAG) assay and [35S]sulfated GAG synthesis; collagen content by hydroxyproline assay; and mitogenic response by [3H]thymidine incorporation into DNA and fluorometric assay of total DNA concentration.	Glycosaminoglycans	111-128	insulin like growth factor 1	Equus caballus	39-44	
9140562-3	1997	PROCEDURE: Triamcinolone acetonide and IGF-1 effects were evaluated by assessing: matrix responses by sulfated glycosaminoglycan (GAG) assay and [35S]sulfated GAG synthesis; collagen content by hydroxyproline assay; and mitogenic response by [3H]thymidine incorporation into DNA and fluorometric assay of total DNA concentration.	Glycosaminoglycans	130-133	insulin like growth factor 1	Equus caballus	39-44	
9140562-3	1997	PROCEDURE: Triamcinolone acetonide and IGF-1 effects were evaluated by assessing: matrix responses by sulfated glycosaminoglycan (GAG) assay and [35S]sulfated GAG synthesis; collagen content by hydroxyproline assay; and mitogenic response by [3H]thymidine incorporation into DNA and fluorometric assay of total DNA concentration.	Glycosaminoglycans	159-162	insulin like growth factor 1	Equus caballus	39-44